Valneva SE (VIE:VLA)
Austria
· Delayed Price · Currency is EUR | Market Cap | 793.36M |
| Revenue (ttm) | 179.91M |
| Net Income (ttm) | -102.16M |
| Shares Out | n/a |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,112 |
| Average Volume | 12,619 |
| Open | 4.722 |
| Previous Close | 4.768 |
| Day's Range | 4.484 - 4.726 |
| 52-Week Range | 2.306 - 5.300 |
| Beta | 1.27 |
| RSI | 55.46 |
| Earnings Date | Mar 16, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.
Financial StatementsNews
VALNEVA Declaration of shares and voting rights: February 28, 2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlo...
Valneva to Participate in Upcoming Investor Conferences
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming inves...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following success...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and pro...
Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom
Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s singl...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's sing...
VALNEVA Declaration of shares and voting rights: January 31, 2026
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon.
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research...
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical researc...
Valneva, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 700 points on Tuesday. Shares of Valneva SE (NASDAQ: VALN) fell sharply in pre- market trading . Valneva disclosed that...
Valneva Withdraws Chikungunya Vaccine IXCHIQ Applications In U.S. Amid FDA Suspension
(RTTNews) - Valneva SE (VALN), a specialty vaccine company, announced that it has voluntarily withdrawn both the biologics license application (BLA) and Investigational New Drug (IND) application for ...
Valneva (VALN) Withdraws Chikungunya Vaccine Applications in the U.S.
Valneva (VALN) Withdraws Chikungunya Vaccine Applications in the U.S.
Valneva withdraws application for standard US approval of its chikungunya shot
French drugmaker Valneva said on Monday it has voluntarily withdrawn its application seeking standard approval of its chikungunya vaccine in the United States after the FDA suspended the shot's licens...
Valneva Provides Update on Chikungunya Vaccine IXCHIQ
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19...
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biolog...
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with e...
Valneva SE - Declaration of voting rights - December 2025
Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon
Valneva (VALN) Ends Vaccine Licensing Deal with Serum Institute
Valneva (VALN) Ends Vaccine Licensing Deal with Serum Institute
Valneva (VALN) Reclaims Chikungunya Vaccine Rights to Enhance Global Reach
Valneva (VALN) Reclaims Chikungunya Vaccine Rights to Enhance Global Reach
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company t...
Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine
Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ
IXCHIQ was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, a...
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Ph...
VALNEVA Declaration of shares and voting rights: November 30, 2025
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15 . Lyme disease is a bacterial infect...